DE VLAM, Kurt, Peter TAYLOR, Philip J. MEASE, Paul PELOSO, Dieter WETZEL, Nicolai BRUN, Brian WIENS, Jan BRANDT-JUERGENS, Edit DRESCHER, Eva DOKOUPILOVÁ, Anna ROWINSKA-OSUCH, Nadia Abdel-Kader MARTIN and Frank BEHRENS. Izokibep Demonstrates Clinically Relevant Efficacy Benefits on Enthesitis, Dactylitis and Nail Outcomes in Active PsA Patients: A 16-week Randomized, Placebo-controlled Trial. 2022. ISSN 2326-5191.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Izokibep Demonstrates Clinically Relevant Efficacy Benefits on Enthesitis, Dactylitis and Nail Outcomes in Active PsA Patients: A 16-week Randomized, Placebo-controlled Trial
Authors DE VLAM, Kurt, Peter TAYLOR, Philip J. MEASE, Paul PELOSO, Dieter WETZEL, Nicolai BRUN, Brian WIENS, Jan BRANDT-JUERGENS, Edit DRESCHER, Eva DOKOUPILOVÁ (203 Czech Republic, belonging to the institution), Anna ROWINSKA-OSUCH, Nadia Abdel-Kader MARTIN and Frank BEHRENS.
Edition 2022.
Other information
Original language English
Type of outcome Conference abstract
Field of Study 30104 Pharmacology and pharmacy
Country of publisher United States of America
Confidentiality degree is not subject to a state or trade secret
Impact factor Impact factor: 13.300
RIV identification code RIV/00216224:14160/22:00128081
Organization unit Faculty of Pharmacy
ISSN 2326-5191
UT WoS 000877386506127
Keywords in English izokibep; enthesitis; dactylitis; nail outcomes; clinical trial
Tags rivok, ÚFT
Tags International impact
Changed by Changed by: JUDr. Sabina Krejčiříková, učo 383857. Changed: 19/1/2023 09:41.
Abstract
PsA is a chronic, inflammatory disease with multiple manifestations, with arthritis and skin involvement. Other areas of inflammation include enthesitis, dactylitis and nail involvement. Unresolved enthesitis leads to chronic pain and reduced quality of life1. IL-17 inhibitors have demonstrated benefits across multiple disease features. Izokibep is a unique IL-17A inhibitor with high potency (0.3 pM), small size (18.6 kD) and half-life extending albumin binding. The purpose is to assess the efficacy of izokibep 40 mg Q2W and 80 mg Q2W versus placebo on measures of enthesitis (most common being Leeds Enthesitis Index (LEI), as well as SPARCC), dactylitis and nails, and explore how these disease features impact quality of life (PsAID questionnaire) over 16 weeks. Drug safety was evaluated.
PrintDisplayed: 4/9/2024 05:42